An Update on the Clinical Science and Treatment of Patients with Metastatic Melanoma

Recent advancements in research have allowed for the development of therapeutic options for the treatment of metastatic melanoma. This CME program will review current clinical trial data as well as present newer technologies and advances for the clinical evaluation, diagnosis, and management of suspicious pigmented lesions.  Recent treatment guidelines and recommendations will also be reviewed in order to better understand how to care for patients with metastatic melanoma. This activity will bring physicians and other health care providers up-to-date on the science of metastatic melanoma.  


Oncologists, dermatologists, and other healthcare clinicians responsible for the care of patients with melanoma.


Upon completion of this activity, participants will be able to:

  1. Explain recent treatment guidelines and recommendations for the care of patients with metastatic melanoma.

  2. Examine the mechanisms of action, as well as supporting clinical trial data for current and emerging therapies.

  3. Incorporate recent clinical data into the development of treatment plans for the patient with metastatic melanoma.



Orit Markowitz, MD
Director of Pigmented Lesions and Skin Cancer
Assistant Professor of Dermatology
Mount Sinai Medical Center
New York, New York

Darrell Rigel, MD
Clinical Professor of Dermatology
New York University School of Medicine
New York, New York

Philip Friedlander, MD, PhD
Director of Melanoma Medical Oncology Program
Assistant Professor Division of Hematology Oncology
Assistant Professor Department of Dermatology
Mount Sinai School of Medicine
The Tisch Cancer Institute
New York, New York


Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:



Relationship Identified With:

Orit Markowitz, MD

Consultant/Advisor: 3-ge; Amgen Inc; Caliber I.D.; LEO Pharma Inc; MELA Sciences, Inc.; Micheison Diagnostics Ltd

Darrell Rigel, MD, MS

Consultant/Advisor: Beiersdorf, Inc.; Ferndale Laboratories, Inc.; Genentech, Inc.; LEO Pharm, US; Medicis Pharmaceutical Corporation; MelaSciences

Stock Ownership: Precision Dermatology


Philip Friedlander, MD, PhD


Consultant/Advisor: GlaxoSmithKline

Stock Ownership: Incyte Corporation; Merrimack Pharmaceuticals, Inc.; Seattle Genetics, Inc.

Research Grant: Celgene Corporation; Genentech Pharmaceuticals, Inc.


Planners, Managers, ReviewersSandy Breslow; Brynne Hunter; Timothy Hayes, MD, PhD; Kristen Scollon; Emma Gilmartin; Jaimie Kelly; and Bernard Abrams, MD hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. 

Financial Support

This activity has been supported by an independent educational grant from Amgen Inc.

Provider Information

Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.

Course Open Date: May 15, 2015 | Course Expiration Date: May 14, 2016

CME Credit (Physicians)

The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

CME Inquiries/Special Needs

For all CME inquiries or special needs, please contact

Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, AcademicCME and Amgen Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Course opens: 
Course expires: 
Please login or register to take this course.